Following a midstage trial showing its fast skeletal muscle activator, tirasemtiv, delivered respiratory and muscular benefits to patients with amyotrophic lateral sclerosis (ALS) despite missing its primary endpoint, Cytokinetics Inc. is launching a phase III trial of the drug to measure its impact on those factors and others, after conversations with regulators gave it confidence to pursue approval.